可溶性ST2作为接受球囊肺动脉血管成形术治疗的慢性血栓栓塞性肺动脉高压患者早期并发症的生物标志物
Soluble ST2 as a Biomarker for Early Complications in Patients with Chronic Thromboembolic Pulmonary Hypertension Treated with Balloon Pulmonary Angioplasty.
作者信息
Banaszkiewicz Marta, Pietrasik Arkadiusz, Florczyk Michał, Kędzierski Piotr, Piłka Michał, Mańczak Rafał, Kochman Janusz, Opolski Grzegorz, Torbicki Adam, Kurzyna Marcin, Darocha Szymon
机构信息
Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, Centre of Postgraduate Medical Education, European Health Center Otwock, 05-400 Otwock, Poland.
Department and Faculty of Cardiology, Medical University of Warsaw, 02-097 Warsaw, Poland.
出版信息
Diagnostics (Basel). 2021 Jan 16;11(1):133. doi: 10.3390/diagnostics11010133.
BACKGROUND
The aim of the study was to assess soluble ST2 (sST2) concentration and its dynamic changes in the periprocedural period in patients with chronic thromboembolic pulmonary hypertension (CTEPH) treated with balloon pulmonary angioplasty (BPA).
METHODS
We prospectively analyzed 57 procedures of BPA performed in 37 patients with CTEPH. Biomarkers, such as N-terminal pro B-type natriuretic peptide (NT-proBNP), troponin T (TnT), and sST2 were assessed at four time points: Before the BPA procedure, 24 h and 48 h after the procedure, and at the discharge from hospital. Each postprocedural period was assessed for complications.
RESULTS
Before the BPA procedure, median sST2 concentration was 26.56 ng/mL (IQR: 16.66-40.83 ng/mL). sST2 concentration was significantly higher 24 h and 48 h after the BPA compared to the baseline measurements (33.31 ng/mL (IQR: 20.81-62.56), = 0.000 and 27.45 ng/mL (IQR: 17.66-54.45), = 0.028, respectively). sST2 level 24 h after the BPA procedure was significantly higher in the group with complications compared to the group without complications in the postprocedural period (97.66 ng/mL (IQR: 53.07-126.18) vs. 26.86 ng/mL (IQR: 19.10-40.12), = 0.000).
CONCLUSIONS
sST2 concentration in patients with CTEPH treated with BPA changes significantly in the postprocedural period and is significantly higher in the group with complications in postprocedural period.
背景
本研究旨在评估接受球囊肺动脉血管成形术（BPA）治疗的慢性血栓栓塞性肺动脉高压（CTEPH）患者围手术期可溶性ST2（sST2）浓度及其动态变化。
方法
我们前瞻性分析了37例CTEPH患者接受的57次BPA手术。在四个时间点评估生物标志物，如N末端B型利钠肽原（NT-proBNP）、肌钙蛋白T（TnT）和sST2：BPA手术前、手术后24小时和48小时以及出院时。对每个术后阶段的并发症进行评估。
结果
BPA手术前，sST2浓度中位数为26.56 ng/mL（四分位间距：16.66 - 40.83 ng/mL）。与基线测量值相比，BPA术后24小时和48小时sST2浓度显著更高（分别为33.31 ng/mL（四分位间距：20.81 - 62.56），P = 0.000和27.45 ng/mL（四分位间距：17.66 - 54.45），P = 0.028）。术后24小时，术后出现并发症的组sST2水平显著高于未出现并发症的组（97.66 ng/mL（四分位间距：53.07 - 126.18） vs. 26.86 ng/mL（四分位间距：19.10 - 40.12），P = 0.000）。
结论
接受BPA治疗的CTEPH患者术后sST2浓度发生显著变化，且术后出现并发症的组sST2浓度显著更高。
Zotero 插件